Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

Abstract Background Tremelimumab is an antibody that blocks CTLA-4 and demonstrates clinical efficacy in a subset of advanced melanoma patients. An unmet clinical need exists for blood-based response-predictive gene signatures to facilitate clinically effective and cost-efficient use of such immunot...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Philip Friedlander, Karl Wassmann, Alan M. Christenfeld, David Fisher, Chrisann Kyi, John M. Kirkwood, Nina Bhardwaj, William K. Oh
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2017-08-01
coleção:	Journal for ImmunoTherapy of Cancer
Assuntos:	Melanoma Biomarker Tremelimumab CTLA-4 Predictive
Acesso em linha:	http://link.springer.com/article/10.1186/s40425-017-0272-z
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!